BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 19275498)

  • 1. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal.
    ; Mocroft A; Sterne JA; Egger M; May M; Grabar S; Furrer H; Sabin C; Fatkenheuer G; Justice A; Reiss P; d'Arminio Monforte A; Gill J; Hogg R; Bonnet F; Kitahata M; Staszewski S; Casabona J; Harris R; Saag M
    Clin Infect Dis; 2009 Apr; 48(8):1138-51. PubMed ID: 19275498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased non-AIDS mortality among persons with AIDS-defining events after antiretroviral therapy initiation.
    Pettit AC; Giganti MJ; Ingle SM; May MT; Shepherd BE; Gill MJ; Fätkenheuer G; Abgrall S; Saag MS; Del Amo J; Justice AC; Miro JM; Cavasinni M; Dabis F; Monforte AD; Reiss P; Guest J; Moore D; Shepherd L; Obel N; Crane HM; Smith C; Teira R; Zangerle R; Sterne JA; Sterling TR;
    J Int AIDS Soc; 2018 Jan; 21(1):. PubMed ID: 29334197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in AIDS-defining illnesses in a London Clinic, 1987-1998.
    Mocroft A; Sabin CA; Youle M; Madge S; Tyrer M; Devereux H; Deayton J; Dykhoff A; Lipman MC; Phillips AN; Johnson MA
    J Acquir Immune Defic Syndr; 1999 Aug; 21(5):401-7. PubMed ID: 10458621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential impact of combined antiretroviral therapy on the survival of italian patients with specific AIDS-defining illnesses.
    Conti S; Masocco M; Pezzotti P; Toccaceli V; Vichi M; Boros S; Urciuoli R; Valdarchi C; Rezza G
    J Acquir Immune Defic Syndr; 2000 Dec; 25(5):451-8. PubMed ID: 11141245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postpartum discontinuation of antiretroviral therapy and risk of maternal AIDS-defining events, non-AIDS-defining events, and mortality among a cohort of HIV-1-infected women in the United States.
    Melekhin VV; Shepherd BE; Jenkins CA; Stinnette SE; Rebeiro PF; Bebawy SS; Rasbach DA; Hulgan T; Sterling TR
    AIDS Patient Care STDS; 2010 May; 24(5):279-86. PubMed ID: 20438375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [AIDS and injecting drug use: survival determinants in the highly active antiretroviral therapy era].
    Zucchetto A; Bruzzone S; De Paoli A; Regine V; Pappagallo M; Dal Maso L; Serraino D; Rezza G; Suligoi B
    Epidemiol Prev; 2009; 33(4-5):184-9. PubMed ID: 20124634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART)in a London clinic.
    Ives NJ; Gazzard BG; Easterbrook PJ
    J Infect; 2001 Feb; 42(2):134-9. PubMed ID: 11531320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mortality Risk After AIDS-Defining Opportunistic Illness Among HIV-Infected Persons--San Francisco, 1981-2012.
    Djawe K; Buchacz K; Hsu L; Chen MJ; Selik RM; Rose C; Williams T; Brooks JT; Schwarcz S
    J Infect Dis; 2015 Nov; 212(9):1366-75. PubMed ID: 26044289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival of AIDS patients according to type of AIDS-defining event. The AIDS in Europe Study Group.
    Mocroft AJ; Lundgren JD; d'Armino Monforte A; Ledergerber B; Barton SE; Vella S; Katlama C; Gerstoft J; Pedersen C; Phillips AN
    Int J Epidemiol; 1997 Apr; 26(2):400-7. PubMed ID: 9169177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study.
    Ledergerber B; Egger M; Erard V; Weber R; Hirschel B; Furrer H; Battegay M; Vernazza P; Bernasconi E; Opravil M; Kaufmann D; Sudre P; Francioli P; Telenti A
    JAMA; 1999 Dec; 282(23):2220-6. PubMed ID: 10605973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of AIDS-defining events at initiation of antiretroviral therapy on long-term mortality of HIV/AIDS patients in Southwestern China: a retrospective cohort study.
    Huang Y; Zhou O; Zheng Z; Xu Y; Shao Y; Qin C; Qin F; Lai J; Liu H; Chen R; Ye L; Liang H; Qin X; Jiang J
    AIDS Res Ther; 2020 Jul; 17(1):44. PubMed ID: 32680536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical profile of end-stage AIDS in the era of highly active antiretroviral therapy.
    Welch K; Morse A;
    AIDS Patient Care STDS; 2002 Feb; 16(2):75-81. PubMed ID: 11874639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Causes of the first AIDS-defining illness and subsequent survival before and after the advent of combined antiretroviral therapy.
    Grabar S; Lanoy E; Allavena C; Mary-Krause M; Bentata M; Fischer P; Mahamat A; Rabaud C; Costagliola D;
    HIV Med; 2008 Apr; 9(4):246-56. PubMed ID: 18366449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of opportunistic disease on survival in patients with HIV infection.
    Chaisson RE; Gallant JE; Keruly JC; Moore RD
    AIDS; 1998 Jan; 12(1):29-33. PubMed ID: 9456252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Higher rates of AIDS during the first year of antiretroviral therapy among migrants: the importance of tuberculosis.
    ; Shepherd BE; Jenkins CA; Parrish DD; Glass TR; Cescon A; Masabeu A; Chene G; de Wolf F; Crane HM; Jarrin I; Gill J; del Amo J; Abgrall S; Khaykin P; Lehmann C; Ingle SM; May MT; Sterne JA; Sterling TR
    AIDS; 2013 May; 27(8):1321-9. PubMed ID: 23925379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pneumocystis prophylaxis and survival in patients with advanced human immunodeficiency virus infection treated with zidovudine. The Zidovudine Epidemiology Group.
    Chaisson RE; Keruly J; Richman DD; Moore RD
    Arch Intern Med; 1992 Oct; 152(10):2009-13. PubMed ID: 1417373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in survival after acquired immunodeficiency syndrome (AIDS): 1984-1991.
    Jacobson LP; Kirby AJ; Polk S; Phair JP; Besley DR; Saah AJ; Kingsley LA; Schrager LK
    Am J Epidemiol; 1993 Dec; 138(11):952-64. PubMed ID: 7903022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paradoxical immune reconstitution inflammatory syndrome in HIV-infected patients treated with combination antiretroviral therapy after AIDS-defining opportunistic infection.
    Achenbach CJ; Harrington RD; Dhanireddy S; Crane HM; Casper C; Kitahata MM
    Clin Infect Dis; 2012 Feb; 54(3):424-33. PubMed ID: 22095568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival improvement of AIDS-related progressive multifocal leukoencephalopathy in the era of protease inhibitors. Clinical Epidemiology Group. French Hospital Database on HIV.
    Tassie JM; Gasnault J; Bentata M; Deloumeaux J; Boué F; Billaud E; Costagliola D
    AIDS; 1999 Oct; 13(14):1881-7. PubMed ID: 10513646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy.
    Marin B; Thiébaut R; Bucher HC; Rondeau V; Costagliola D; Dorrucci M; Hamouda O; Prins M; Walker S; Porter K; Sabin C; Chêne G
    AIDS; 2009 Aug; 23(13):1743-53. PubMed ID: 19571723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.